Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Limaprost alfadex - Ono Pharmaceutical/Sumitomo Pharma

Drug Profile

Limaprost alfadex - Ono Pharmaceutical/Sumitomo Pharma

Alternative Names: Limaprost; Limaprost alphadex; ONO-1206; OP-1206; Opalmon; Opast; Prorenal

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma; Ono Pharmaceutical
  • Developer Meiji Seika Pharma; Ono Pharmaceutical; Sumitomo Pharma; Yungjin Pharm Co
  • Class Peripheral vasodilators; Prostaglandins; Small molecules; Unsaturated fatty acids; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Intermittent claudication; Thromboangiitis obliterans
  • Discontinued Carpal tunnel syndrome; Spondylosis

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 05 Mar 2020 Ono Pharmaceutical and Nichi-Iko Pharmaceutical enters into an licensing agreement to develop and market Limaprost alfadex for its improved formulation
  • 29 Jun 2018 Preregisteration for Intermittent claudication in Thailand (PO) prior to June 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top